Relmada therapeutics appoints Dr. Max Kates to propel NDV-01 toward phase 3
Phase 3 program for NDV-01 in non-muscle invasive bladder cancer expected to begin in the first half of 2026
Phase 3 program for NDV-01 in non-muscle invasive bladder cancer expected to begin in the first half of 2026
Ultra-high purity surfactant for biologics and parenteral drug formulations
The complex four-hour surgery was performed by a multidisciplinary team of doctors
This partnership aims to address the growing demand for high-quality diagnostics in metropolitan areas
CRL shall invest another Rs. 200 crore for creation of additional beds
Max Healthcare Institute has reported total income of Rs. 1,748.30 crores during the period ended September 30, 2024
The acquisition is based on an enterprise value of Rs. 1,660 crore
 
        Subscribe To Our Newsletter & Stay Updated